1. Page NC, Read WL, Tierney RM, et al.: The epidemiology of small cell lung carcinoma [abstract]? Proc Am Soc Clin Oncol 2002, 21:305a.
2. Ettinger DS, Seiferheld WF, Abrams RA, et al.: Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 95-09 [abstract]? Proc Am Soc Clin Oncol 2000, 19:490a.
3. Niell H, Herndon JE, Miller AA, et al.: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive small cell lung cancer (ED-SCLC) [abstract]? Proc Am Soc Clin Oncol 2002, 21:293a.
4. Kosmidis PA, Samanta E, Fountzilas G, et al.: Cisplatin/ etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Group for Lung Cancer Trials? Semin Oncol 1994, 21(Suppl 3):23–30. Kosmidis et al. report that 300 mg/m2 of carboplatinum is an equivalent to cisplatin given 50 mg/m2 on days 1 and 2. However, this trial is not powered to establish equivalence.
5. Work E, Nielsen OS, Bentzen SM, et al.: Randomized study of initial versus late chest irradiation combined with chemotherapy in limited small-cell lung cancer? J Clin Oncol 1997, 15:3030–3037.